ACC 23: BMAD Trial: μCor in Ambulatory Decompensated Heart Failure

Подробнее о видео

We are joined on-site by Dr John Boehmer (Penn State Health, US) to discuss the findings of the BMAD-TX Trial, originally revealed at ACC 2023 (Zoll Medical Corporation). In this study, investigators aimed to assess the impact of a novel wearable sensor, the Microcor, (μCor™) in the management of heart failure. 266 patients with ambulatory decompensated heart failure were enrolled in the study.

The trial showed that managing heart failure using a threshold alert from the HFMS system results in 38% relative risk reduction in heart failure readmissions following hospitalisation.

Questions:
-What is the importance of this study?
-Could you please tell us about the μCor system?
-What was the patient population and study design?
-What are the main findings?
-How can these findings be put into clinical practice?
-What further research is needed?

Recorded on site at ACC 2023, New Orleans.

Visit Radcliffe Cardiology:

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook:
Follow us on Twitter: